Who
George L. Sing
Director
Company insider
Files Form 4 as: Director, Regeneron Pharmaceuticals.
In numbers
- Trades disclosed
- 267
- Buys
- 2
- Sells
- 50
- Bought
- $448K
- Sold
- $167.3M
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 3 Jan 2006
- Last trade
- 2 Nov 2026
- Last filed
- 4 Nov 2026
Companies traded
Activity over time
1 Dec 2024 – 1 Nov 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Nov 2026filed 4 Nov 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $2.9M7,830 at $376.69 | filing |
| 2 Nov 2026filed 4 Nov 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.0M1,040 at $967.07 | filing |
| 2 Nov 2026filed 4 Nov 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $194K200 at $970.18 | filing |
| 2 Nov 2026filed 4 Nov 2026 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,830 at $0.00 | filing |
| 2 Nov 2026filed 4 Nov 2026 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,439 at $0.00 | filing |
| 2 Nov 2026filed 4 Nov 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $2.8M7,439 at $380.95 | filing |
| 2 Nov 2026filed 4 Nov 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.2M1,224 at $960.57 | filing |
| 2 Nov 2026filed 4 Nov 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $519K540 at $961.85 | filing |
| 2 Nov 2026filed 4 Nov 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $2.4M2,522 at $962.61 | filing |
| 2 Nov 2026filed 4 Nov 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $4.2M4,338 at $963.47 | filing |
| 2 Nov 2026filed 4 Nov 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $2.6M2,670 at $964.57 | filing |
| 2 Nov 2026filed 4 Nov 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $6.8M7,073 at $965.38 | filing |
| 2 Nov 2026filed 4 Nov 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.5M1,522 at $966.27 | filing |
| 2 Jan 2026filed 6 Jan 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —155 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,962 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,962 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —155 at $0.00 | filing |
| 30 Dec 2025filed 31 Dec 2025 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,212 at $0.00 | filing |
| 30 Dec 2025filed 31 Dec 2025 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $4.8M9,212 at $520.01 | filing |
| 30 Dec 2025filed 31 Dec 2025 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $4.8M6,188 at $774.03 | filing |
News
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $812.00 Price Target at Sanford C. BernsteinREGN · themarketsdaily.com · 2 Nov 2026Regeneron expects 2027 R&D expense to rise by a mid-teens percentage while recording a $1B Sanofi upfront payment in Q4 (NASDAQ:REGN)REGN · seekingalpha.com · 30 Oct 2026
0 headlines in the last 90 days name George L. Sing; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.